Quasar Medical, a global leader in the manufacturing of interventional and complex minimally invasive devices, has officially signed a definitive agreement to acquire the design and development contract manufacturing businesses of Nordson Corporation (NASDAQ:NDSN) in Galway, Ireland, and Tecate, Mexico. This strategic acquisition, set to close in the third quarter of calendar 2025, aims to enhance Quasar’s capabilities as a full-service Contract Development and Manufacturing Organization (CDMO), providing comprehensive solutions from initial design through to large-scale production.
The integration of the Galway and Tecate facilities into Quasar’s broad global platform will bring specialized expertise in complex balloon and catheter design, rapid prototyping, and efficient near-shore device assembly. Both facilities not only contribute advanced knowledge and IP-generating capabilities but also expand Quasar’s footprint with FDA-registered and ISO-certified operations and a highly skilled workforce strategically located in two prominent MedTech hubs.
“This is more than just a bolt-on acquisition; it signifies the next chapter for Quasar,” stated Alex Wallstein, CEO of Quasar Medical. “We are now uniquely equipped to offer fully integrated interventional solutions—from concept to finished device scale-up—while further diversifying into a global CDMO partner with increased capacity in both Ireland and Mexico to complement our established presence in Asia.”
Dave Zgonc, Vice President of Nordson MEDICAL Interventional Solutions, praised the teams in Galway and Tecate for their dedication and expertise. “We’re extremely proud of the highly skilled teams in Galway and Tecate, their expertise, and the customer partnerships they’ve built over the years in our finished device contract manufacturing business,” he noted.
With the acquisition, Quasar Medical expands its operational reach to include 10 facilities across North America, Europe, Israel, and Asia, now boasting 800,000 square feet of manufacturing space and over 4,200 employees, including a significant number of engineers. The Galway facility will focus on design, prototyping, and product development, while Tecate will emphasize scalable manufacturing and assembly.
Customer Benefits and Strategic Impact
This strategic acquisition is poised to offer multiple benefits to Quasar Medical’s customers, including:
- Integrated design-for-manufacturing and scalable production
- Quicker program transfers and enhanced market readiness
- Near-shore operations catering to U.S. customers
- Manufacturing strategies tailored to balance speed, quality, and cost
- Robust quality infrastructure compliant with FDA and ISO standards across all facilities
By solidifying its capabilities, Quasar Medical is poised to support global OEMs and innovators efficiently, providing speed, flexibility, innovation, and precision from the initial concept through to the delivery of finished devices. The company plans to work closely with Nordson to ensure a seamless transition for all customers and suppliers, with the Galway and Tecate sites fully integrated into the Quasar platform following the closing.
